FDA approves first LazandaR nasal spray

Wednesday, July 6, 2011

Archimedes Pharma and its subsidiary, Archimedes Pharma U.S., have won FDA approval of LazandaR (fentanyl) nasal spray for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

[Read More]